Company News

03/04/2024

VIPC’s Virginia Venture Partners Invests in The Tiny Cargo Company to Scale and Protect Novel Drug Delivery Platform

The Virginia Innovation Partnership Corporation (VIPC) today announced that Virginia Venture Partners (VVP), its equity investment program, has invested in The Tiny Cargo Company. The Roanoke, Va.-based spinout from Virginia Tech is developing a patent-pending drug delivery platform that utilizes milk-derived exosomes and is positioned to be the B2B global leader in supply and application

03/01/2024

ivWatch Partners with National Infusion Center Association (NICA)

ivWatch, LLC, the IV safety company, today announced that it has partnered with the National Infusion Center Association (NICA), an independent, nonprofit trade association and accrediting body dedicated to representing ambulatory outpatient care settings where provider-administered biologics and specialty medications are prepared and administered. In alignment, ivWatch and NICA are partnering with an emphasis on

02/29/2024

VCU Health leads clinical trial for new treatment to help people with bowel control problems

A research team at VCU Health is leading a clinical trial to assess a novel treatment for fecal incontinence or sudden loss of control over bowel movements. The therapy involves implanting a bioengineered sphincter derived from the patient’s native cells to help them regain control of their bowels. The implantation surgery for the clinical trial

02/21/2024

SRI selected as spoke for both ARPA-H Customer Experience Hub and Investor Catalyst Hub

SRI has been selected by the Advanced Research Projects Agency for Health (ARPA-H) to serve as a spoke within the Customer Experience Hub (CX Hub) and the Investor Catalyst Hub (IC Hub), as part of ARPANET-H, a nationwide health innovation network launched in September 2023. “Hundreds of organizations have been selected to join each network.

02/21/2024

ReAlta Life Sciences Announces Dosing of First Patient in Phase 2 Trial of RLS-0071 for Acute Exacerbations of Chronic Obstructive Pulmonary Disease

ReAlta Life Sciences, Inc. (“ReAlta” or the “Company”), a mid-stage clinical biotech company dedicated to saving lives by rebalancing the inflammatory response to address life-threatening diseases, announced enrollment of the first patient in a Phase 2 clinical trial evaluating the safety and efficacy of RLS-0071, an investigational new drug based on ReAlta’s novel EPICC peptide

02/12/2024

CEL-SCI Announces Pricing of $7.75 Million Public Offering of Common Stock

CEL-SCI Corporation (“CEL-SCI” or the “Company”) (NYSE American: CVM), a Phase 3 cancer immunotherapy company, today announced the pricing of an offering of 3,875,000 shares of its common stock at an offering price of $2.00 per share, for gross proceeds of $7.75 million, before deducting underwriting discounts and offering expenses. All of the shares of

02/08/2024

Quoin Pharmaceuticals Files U.S. and International Patent Applications for Novel Netherton Syndrome Combination Product

Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a specialty pharmaceutical company exclusively focused on the development and commercialization of innovative therapies that treat rare and orphan diseases, today announced it has filed U.S. and International patent applications for a novel combination product as a potential treatment of Netherton Syndrome. This new product combines

02/05/2024

Serpin Pharma Secures $900,000 BIRD Foundation Grant for Clinical Trial in AMI Treatment

Serpin Pharma, a pioneering clinical-stage pharmaceutical company headquartered in Virginia, has been awarded a competitive $900,000 grant by the Bi-national Industrial Research and Development (BIRD) Foundation. The BIRD Foundation promotes collaborations between U.S. and Israeli companies in various technological sectors for joint product development This grant is designated for the advancement of a randomized controlled

01/30/2024

Cerillo® Announces Partnership with Opentrons to Deliver Automated Microbiome Research Solutions

Cerillo®, a technology company developing advanced research platforms for microbiome studies, today announced a partnership with Opentrons Labworks, Inc., a leading force in lab automation. The collaboration not only grants researchers access to entry-level lab automation but also extends the reach of Cerillo’s comprehensive suite of microbiome research tools, fostering standardization and efficiency in laboratory

01/18/2024

Children’s National Novel AI platform matches cardiologists in detecting rheumatic heart disease

Artificial intelligence (AI) has the potential to detect rheumatic heart disease (RHD) with the same accuracy as a cardiologist, according to new research demonstrating how sophisticated deep learning technology can be applied to this disease of inequity. The work could prevent hundreds of thousands of unnecessary deaths around the world annually. Developed at Children’s National

01/18/2024

Adial Announces Appointment of Tony Goodman as Chief Operating Officer

Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced the appointment of Tony Goodman as Chief Operating Officer. A highly accomplished pharmaceutical industry executive and member of Adial’s Board of Directors since 2017, Mr.

01/16/2024

Two Additional Organic Compliance Listings Obtained for AgroSpheres Novel Encapsulation Platform for Use in Organic Crop Production

AgroSpheres, Inc., an agricultural biobased solutions developer, recently received certificates attesting to the organic input compliance of its proprietary encapsulation technology, AgroSpheres® Microbially-Derived Minicells (also known as the AgriCell), and its formulated encapsulated thyme oil product, Thyme Oil 26% LC Biofungicide from the Organic Materials Review Institute (OMRI). OMRI, the leading certifier of organic inputs

01/16/2024

Caldic announces partnership with BIO-CAT to bring innovative probiotics to the Companion Animal Health and Nutrition industry

BIO-CAT, Inc., an industry leading probiotic manufacturer, has agreed to partner with global distribution solutions provider Caldic North America to bring their proprietary probiotic strains and OPTIFEED® branded solutions to the Companion Animal Health and Nutrition market in North America. This agreement secures a rapid go-to-market strategy for BIO-CAT, leveraging Caldic’s leadership position in the Companion

01/09/2024

Virginia Catalyst Announces Grant Round 15 Awarded Projects

The Virginia Catalyst, also known as the Virginia Biosciences Health Research Corporation (VBHRC), today announced that it has awarded $2.2 million in grants to four life and bioscience projects in the Commonwealth of Virginia. These four collaborative projects, involving Virginia research universities and industry partners, were awarded through Virginia Catalyst Grant Round 15 to address

01/04/2024

Aditxt reaches deal to acquire maker of Phexxi

Aditxt, a biotech company based in Richmond, expects to purchase California-based contraceptive maker Evofem Biosciences for $100 million, taking on the business’s debt of up to $18 million, according to Aditxt’s announcement. Both companies’ boards have unanimously approved the acquisition, which is expected to close in the first half of the year. Evofem produces Phexxi,

01/03/2024

Bonumose’s Tagatose Certified As Plant-Based & Vegetarian

For the first time, tagatose has been certified as Plant-Based and Vegetarian. Tagatose is an ultra-low glycemic index sugar substitute found in tiny quantities in plants such as apples, pineapples, and the sap of a tree related to the cocoa tree. But because tagatose is found in nature is such small amounts, for commercial purposes

01/03/2024

ReAlta Life Sciences Strengthens Board of Directors with Appointment of Three Accomplished Biotechnology Executives

ReAlta Life Sciences, Inc. (“ReAlta” or the “Company”), a mid-stage clinical biotech company dedicated to saving lives by rebalancing the inflammatory response to address life-threatening diseases, announced the appointment of three seasoned biotechnology executives, Christi Shaw, Mert Aktar, and David Marek, to its Board of Directors, effective immediately. “We are delighted to welcome Christi Shaw,

12/11/2023

$90 Million Investment to Launch “Virginia’s Research Triangle” Network Among at UVA, VA Tech and VCU

Governor Youngkin has announced that Virginia will make a significant investment to launch a biotechnology, life sciences, and pharmaceutical manufacturing network to foster collaboration among three of the Commonwealth’s major existing university research institutions. In his upcoming biennial budget, scheduled to be released on December 20th, the Governor will include a total of $90 million

12/05/2023

Industry Leader and Globally Recognized Patient Advocate John F. Crowley Appointed to Lead BIO as President & CEO

The Biotechnology Innovation Organization (BIO) is proud to announce that industry leader and military veteran John F. Crowley will be its new President and CEO, effective March 4. He will replace Rachel King, a longtime BIO board member and industry trailblazer who has served as BIO’s CEO on an interim basis for the past year.

12/04/2023

The Lessons Learned from the STEM2VA Internship Program for the Life Sciences Industry

About two years ago, the STEM2VA Program kicked off to provide internship opportunities for Virginia students within the life sciences sector on one side and to facilitate the recruitment process and offset some costs for the employers on another. The program was part of the Virginia Bio-Connect project funded by the GO Virginia grant initiative.

12/04/2023

Phlow Earns B Corp Certification Continuing Its Commitment to Improve Quality, Reliability, and Access to Essential Medications

Phlow Corp., a Public Benefit Corporation,  announced that it has joined a select group of purpose-driven businesses by becoming the first pharmaceutical manufacturer based in America to earn B Corporation™ (B Corp™) certification. The new certification further emphasizes Phlow’s commitment to improving access and availability of domestically produced, high-quality pharmaceuticals and active pharmaceutical ingredients through

11/30/2023

ATCC Announces Award from NIAID to Consolidate its BEI Resources and NIH HIV Reagent Programs

ATCC, the world’s premier biological materials management and standards organization, today announced a seven-year contract from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), to continue the management of the BEI Resources Program. NIAID has made an initial award of over $21.5 million, with further funding

11/30/2023

Acclinate Collaborates with Merck to Increase Clinical Trial Diversity

Acclinate, an expert in health equity through inclusive research, is collaborating with Merck, known as MSD outside the United States and Canada, to help increase participation by members of the Black/African American community in Merck’s oncology clinical studies. “We’re proud to be working with Merck because being a champion for health equity through inclusive research

11/27/2023

cultivate(MD) Capital Funds LP Announces Investment into Nanochon

cultivate(MD) Capital Funds LP, funds that are focused on investments into early-stage medical device companies with innovative technologies, announced today that they have made a significant investment into Nanochon, a Washington, D.C.—based regenerative cartilage innovator. Nanochon develops solutions utilized by sports medicine physicians to treat active patients requiring cartilage restoration.  Nanochon’s Chondrograft™ replaces lost or damaged